Kun-Ming Rau

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy

Heng‐Huan Lee, Ying‐Nai Wang, Weiya Xia et al. · Cancer Cell · 2019 · 387 citations · Full text

Medicine, Immunology, Glycobiology +5

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Jayesh Desai, Sanjeev Deva, Jong Seok Lee et al. · Journal for ImmunoTherapy of Cancer · 2020 · 145 citations · Full text

Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study

Shukui Qin, Ying Cheng, Jun Liang et al. · The Oncologist · 2014 · 98 citations · Full text

Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study

Kun-Ming Rau, Yung‐Chang Lin, Yen-Yang Chen et al. · BMC Cancer · 2015 · 49 citations · Full text

Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan

Wen-Chi Shen, Jen‐Shi Chen, Yu‐Yun Shao et al. · Journal of Pain and Symptom Management · 2017 · 43 citations · Full text

Pain Therapy, Pain Research, Health Sciences +12